Vanguard Capital Management
PTCT icon

Vanguard Capital Management’s PTC Therapeutics PTCT Stock Holding History

Vanguard Capital Management’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$305M Buy
3,739,127
+62,871
+2% +$4.54M 0.01% 913
2026
Q1 		$250M Buy
+3,676,256
New +$260M 0.01% 945

Other funds holding PTCT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $13.8B AUM 163.97% 1-Year Est. Return

Vanguard Capital Management's PTCT Position: Q2 2026 in Review

Vanguard Capital Management increased its PTC Therapeutics (PTCT) stake by 1.7% in Q2 2026, buying an estimated $4.54M and bringing the position to 3,739,127 shares worth $305M. The position accounts for 0.01% of the portfolio, ranked #913.

Vanguard Capital Management first reported a position in PTCT in Q1 2026 and has held it in 2 quarters since. 374 funds tracked by Wall St. Rank hold PTCT as of Q2 2026.

  • Vanguard Capital Management held 3,739,127 shares of PTC Therapeutics worth $305M as of Q2 2026.
  • Vanguard Capital Management bought 62,871 PTC Therapeutics shares in Q2 2026, an estimated $4.54M.
  • PTC Therapeutics made up 0.01% of Vanguard Capital Management's portfolio in Q2 2026, its #913 holding.
  • Vanguard Capital Management first reported a position in PTC Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 374 funds tracked by Wall St. Rank held PTC Therapeutics as of Q2 2026.

Based on Vanguard Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.